Journal ArticleDOI
Association of metformin use with cancer incidence and mortality: A meta-analysis
Reads0
Chats0
TLDR
Metformin can reduce the incidence of overall cancer, liver cancer, pancreatic cancer, colorectal cancer and breast cancer as well as the mortality of Overall cancer, Liver cancer and Breast cancer.About:
This article is published in Cancer Epidemiology.The article was published on 2013-06-01. It has received 242 citations till now. The article focuses on the topics: Cancer & Breast cancer.read more
Citations
More filters
Journal ArticleDOI
Metformin and Cancer in Type 2 Diabetes
TL;DR: Several epidemiologic findings support that hyperinsulinemia is associated with an increased risk of developing endometrial and breast cancers in postmenopausal women without diabetes, and medications such as insulin or secretagogues, which increase circulating insulin levels, may increase the cancer risk.
Journal ArticleDOI
Metformin use reduced the overall risk of cancer in diabetic patients: A study based on the Korean NHIS-HEALS cohort
Ye-Seul Kim,Eun-A Choi,Jae-Woo Lee,Yonghwan Kim,Hyo-Sun You,Ye-Eun Han,Hyeong-Seop Kim,Yoon-Jong Bae,Hee-Taik Kang,Joungyoun Kim +9 more
TL;DR: Diabetic patients receiving met formin treatment, and individuals without diabetes were at lower risk for cancer incidence than diabetic patients without metformin treatment.
Journal ArticleDOI
Precision Medicine in Pancreatic Disease-Knowledge Gaps and Research Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop
Mark E. Lowe,Dana K. Andersen,Richard M. Caprioli,Jyoti S. Choudhary,Zobeida Cruz-Monserrate,Anil K. Dasyam,Chris E. Forsmark,Fred S. Gorelick,Fred S. Gorelick,Joe W. Gray,Mark Haupt,Kimberly A. Kelly,Kenneth P. Olive,Sylvia K. Plevritis,Noa Rappaport,Holger R. Roth,Hanno Steen,S. Joshua Swamidass,Temel Tirkes,Aliye Uc,Kirill Veselkov,David C. Whitcomb,Aida Habtezion +22 more
TL;DR: A workshop on research gaps and opportunities for Precision Medicine in Pancreatic Disease was sponsored by the National Institute of Diabetes and Digestive Kidney Diseases on July 24, 2019, in Pittsburgh.
Journal ArticleDOI
Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents
TL;DR: In this paper , the authors focus on the machine learning methods for the development of new type 2 diabetes mellitus (T2DM) drugs and give an overview of the repurposing potential of the existing antidiabetic agents.
Journal ArticleDOI
When fat becomes an ally of the enemy: adipose tissue as collaborator in human breast cancer.
TL;DR: A review of the paracrine and endocrine role of adipose tissue in breast cancer initiation and progression and a short reflection on therapeutic possibilities is included.
References
More filters
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Bias in meta-analysis detected by a simple, graphical test
TL;DR: Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
Journal ArticleDOI
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
TL;DR: Those on insulin or insulin secretagogues were more likely to develop solid cancers than those on metformin, and combination with met formin abolished most of this excess risk.
Journal ArticleDOI
New Users of Metformin Are at Low Risk of Incident Cancer: A cohort study among people with type 2 diabetes
Gillian Libby,Louise A. Donnelly,Peter T. Donnan,Dario R. Alessi,Dario R. Alessi,Andrew D. Morris,Josie M M Evans +6 more
TL;DR: Results suggest that metformin use may be associated with a reduced risk of cancer in people with type 2 diabetes, and a randomized trial is needed to assess whether met formin is protective in a population at high risk for cancer.
Journal ArticleDOI
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
Andrea Decensi,Matteo Puntoni,Pamela J. Goodwin,Massimiliano Cazzaniga,Alessandra Gennari,Bernardo Bonanni,Sara Gandini +6 more
TL;DR: A comprehensive literature search and meta-analysis of epidemiologic studies to assess the effect of metformin on cancer incidence and mortality in diabetic patients found that the inverse association was significant for pancreatic and hepatocellular cancer, and nonsignificant for colon, breast, and prostate cancer.
Related Papers (5)
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
I. Ben Sahra,Kathiane Laurent,Kathiane Laurent,Agnès Loubat,Agnès Loubat,Sophie Giorgetti-Peraldi,Sophie Giorgetti-Peraldi,Pascal Colosetti,Pascal Colosetti,Patrick Auberger,Patrick Auberger,Jean-François Tanti,Jean-François Tanti,Y. Le Marchand-Brustel,Y. Le Marchand-Brustel,Frédéric Bost,Frédéric Bost +16 more